JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its price objective hoisted by research analysts at JPMorgan Chase & Co. from $167.00 to $168.00 in a report released on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its price objective hoisted by research analysts at JPMorgan Chase & Co. from $167.00 to $168.00 in a report released on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of […]
